Therapeutic modalities of squalenoyl nanocomposites in colon cancer: An ongoing search for improved efficacy

ACS Nano

Volumn 8, Issue 3, 2014, Pages 2018-2032

  Maksimenko, Andrei ^a   Alami, Mouad ^b   Zouhiri, Fatima ^a   Brion, Jean Daniel ^b   Pruvost, Alain ^c   Mougin, Julie ^a   Hamze, Abdallah ^b   Boissenot, Tanguy ^a   Provot, Olivier ^b   Desmaële, Didier ^a   Couvreur, Patrick ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITÉ PARIS SUD   (France)

^c SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

Author keywords

chemotherapy; colon cancer; gemcitabine; isoCA 4 combretastatin isomer; nanomedicine; squalene

Indexed keywords

CELL CULTURE; CELL MEMBRANES; CHEMOTHERAPY; CYTOTOXICITY; DRUG DELIVERY; ISOMERS; MEDICAL NANOTECHNOLOGY; NANOCOMPOSITES; NANOPARTICLES;

ANTI-PROLIFERATIVE; ANTICANCER COMPOUNDS; COLON CANCER; CULTURE VIABILITY; GEMCITABINE; HUMAN COLON CANCER; SQUALENE; THERAPEUTIC MODALITY;

DISEASES;

ANTINEOPLASTIC AGENT; COMBRETASTATIN A4 PHOSPHATE; DEOXYCYTIDINE; DRUG CARRIER; DRUG DERIVATIVE; GEMCITABINE; NANOCOMPOSITE; SQUALENE; STILBENE DERIVATIVE;

ANIMAL; ARTICLE; CELL PROLIFERATION; CHEMISTRY; COLON TUMOR; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; HUMAN; INTRACELLULAR SPACE; METABOLISM; MOUSE; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DEOXYCYTIDINE; DRUG CARRIERS; DRUG DESIGN; HUMANS; INTRACELLULAR SPACE; MICE; NANOCOMPOSITES; SQUALENE; STILBENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897005935     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn500517a     Document Type: Article

References (37)

1. Ma, Y.; Shurin, G. V.; Gutkin, D. W.; Shurin, M. R. Semin. Tumor Associated Regulatory Dendritic Cells Semin. Cancer Biol. 2012, 22, 298-306
2. Hielscher, A. C.; Gerecht, S. Engineering Approaches for Investigating Tumor Angiogenesis: Exploiting the Role of the Extracellular Matrix Cancer Res. 2012, 72, 6089-6096
3. Chekhonin, V. P.; She in, S. A.; Korchagina, A. A.; Gurina, O. I. VEGF in Tumor Progression and Targeted Therapy Curr. Cancer Drug Targets 2012, 13, 1-21
4. Hillen, F.; Griffioen, A. W. Tumour Vascularization: Sprouting Angiogenesis and Beyond Cancer Metastasis Rev. 2007, 26, 489-502
5. Holash, J.; Maisonpierre, P. C.; Compton, D.; Boland, P.; Alexander, C. R.; Zagzag, D.; Yancopoulos, G. D.; Wiegand, S. J. Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF Science 1999, 284, 1994-1998
6. Johannessen, T. C.; Wagner, M.; Straume, O.; Bjerkvig, R.; Eikesdal, H. P. Tumor Vasculature: the Achilles' Heel of Cancer? Expert Opin. Ther. Targets 2013, 17, 7-20
7. Rosenzweig, S. A. Acquired Resistance to Drugs Targeting Receptor Tyrosine Kinases Biochem. Pharmacol. 2012, 83, 1041-1048
8. Gerber, H. P.; Ferrara, N. Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies Cancer Res. 2005, 65, 671-680
9. Escorcia, F. E.; Henke, E.; McDevitt, M. R.; Villa, C. H.; Smith-Jones, P.; Blasberg, R. G.; Benezra, R.; Scheinberg, D. A. Selective Killing of Tumor Neovasculature Paradoxically Improves Chemotherapy Delivery to Tumors Cancer Res. 2010, 70, 9277-9286
10. Jain, R. K. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy Science 2005, 307, 58-62
11. Sengupta, S.; Eavarone, D.; Capila, I.; Zhao, G.; Watson, N.; Kiziltepe, T.; Sasisekharan, R. Temporal Targeting of Tumour Cells and Neovasculature with a Nanoscale Delivery System Nature 2005, 436, 568-572
12. Yang, T.; Wang, Y.; Li, Z.; Dai, W.; Yin, J.; Liang, L.; Ying, X.; Zhou, S.; Wang, J.; Zhang, X. et al. Targeted Delivery of a Combination Therapy Consisting of Combretastatin A4 and Low-Dose Doxorubicin Against Tumor Neovasculature Nanomedicine 2012, 8, 81-92
13. Colon Cancer: Stages and Survival Rates. www.coloncancer.about.com/od/ stagesandsurvivalrates (accessed January 14, 2014).
14. Ba?an, B. J.; S?otwiński, R.; Skopińska-Ró?ewska, E. Role of Angiogenesis and Angiogenic Factors in Colorectal Cancer Cent. Eur. J. Immunol. 2009, 34, 254-260
15. Ahlström, H.; Christofferson, R.; Lörelius, L. E. Vascularization of the Continuous Human Colonic Cancer Cell Line LS 174 T Deposited Subcutaneously in Nude Rats APMIS 1988, 96, 701-710
16. Burdick, M. M.; McCaffery, J. M.; Kim, Y. S.; Bochner, B. S.; Konstantopoulos, K. Colon Carcinoma Cell Glycolipids, Integrins, and Other Glycoproteins Mediate Adhesion to HUVECs Under Flow Am. J. Physiol.: Cell Physiol. 2003, 284, C977-987
17. Ward Ward, S.; Morris, E.; Bansback, N.; Calvert, N.; Crellin, A.; Forman, D.; Larvin, M.; Radstone, D. A Rapid and Systematic Review of the Clinical Effectiveness and Cost-Effectiveness of Gemcitabine for the Treatment of Pancreatic Cancer Health Technol. Assess. 2001, 5, 1-70
18. Wang, H.; Li, M.; Rinehart, J. J.; Zhang, R. Pretreatment with Dexamethasone Increases Antitumor Activity of Carboplatin and Gemcitabine in Mice Bearing Human Cancer Xenografts: In Vivo Activity, Pharmacokinetics, and Clinical Implications for Cancer Chemotherapy Clin. Cancer Res. 2004, 10, 1633-1644
19. García-Manteiga, J.; Molina-Arcas, M.; Casado, F. J.; Mazo, A.; Pastor-Anglada, M. Nucleoside Transporter Profiles in Human Pancreatic Cancer Cells: Role of hCNT1 in 2?,2?-Difluorodeoxycytidine-Induced Cytotoxicity Clin. Cancer Res. 2003, 9, 5000-5008
20. Mackey, J. R.; Mani, R. S.; Selner, M.; Mowles, D.; Young, J. D.; Belt, J. A.; Crawford, C. R.; Cass, C. E. Functional Nucleoside Transporters are Required for Gemcitabine Influx and Manifestation of Toxicity in Cancer Cell Lines Cancer Res. 1998, 58, 4349-4357
21. Couvreur, P.; Stella, B.; Reddy, L. H.; Hillaireau, H.; Dubernet, C.; Desmaële, D.; Lepêtre-Mouelhi, S.; Rocco, F.; Dereuddre-Bosquet, N.; Clayette, P. et al. Squalenoyl Nanomedicines as Potential Therapeutics Nano Lett. 2006, 6, 2544-2548
22. Réjiba, S.; Reddy, L. H.; Bigand, C.; Parmentier, C.; Couvreur, P.; Hajri, A. Squalenoyl Gemcitabine Nanomedicine Overcomes the Low Efficacy of Gemcitabine Therapy in Pancreatic Cancer Nanomedicine 2011, 7, 841-849
23. Reddy, L. H.; Marque, P. E.; Dubernet, C.; Mouelhi, S. L.; Desmaële, D.; Couvreur, P. Preclinical Toxicology (Subacute and Acute) and Efficacy of a New Squalenoyl Gemcitabine Anticancer Nanomedicine J. Pharmacol. Exp. Ther. 2008, 325, 484-490
24. Reddy, L. H.; Renoir, J. M.; Marsaud, V.; Lepetre-Mouelhi, S.; Desmaële, D.; Couvreur, P. Anticancer Efficacy of Squalenoyl Gemcitabine Nanomedicine on 60 Human Tumor Cell Panel and on Experimental Tumor Mol. Pharmaceutics 2009, 6, 1526-1535
25. Reddy, L. H.; Khoury, H.; Paci, A.; Deroussent, A.; Ferreira, H.; Dubernet, C.; Decléves, X.; Besnard, M.; Chacun, H.; Lepêtre- Mouelhi, S. et al. Squalenoylation Favorably Modifies the In Vivo Pharmacokinetics and Biodistribution of Gemcitabine in Mice Drug Metab. Dispos. 2008, 36, 1570-1577
26. Bildstein, L.; Dubernet, C.; Marsaud, V.; Chacun, H.; Nicolas, V.; Gueutin, C.; Sarasin, A.; Bénech, H.; Lepêtre-Mouelhi, S.; Desmaële, D. et al. Transmembrane Diffusion of Gemcitabine by a Nanoparticulate Squalenoyl Prodrug: An Original Drug Delivery Pathway J. Controlled Release 2010, 147, 163-170
27. Hamze, A.; Giraud, A.; Messaoudi, S.; Provot, O.; Peyrat, J. F.; Bignon, J.; Liu, J. M.; Wdzieczak-Bakala, J.; Thoret, S.; Dubois, J. et al. Synthesis, Biological Evaluation of 1,1-Diarylethylenes as a Novel Class of Antimitotic Agents ChemMedChem 2009, 4, 1912-1924
28. Messaoudi, S.; Tréguier, B.; Hamze, A.; Provot, O.; Peyrat, J. F.; Rodrigo De Losada, J.; Liu, J. M.; Bignon, J.; Wdzieczak-Bakala, J.; Thoret, S. et al. Isocombretastatins A versus Combretastatins A: The Forgotten isoCA-4 Isomer as a Highly Promising Cytotoxic and Antitubulin Agent J. Med. Chem. 2009, 52, 4538-4542
29. Cushman, M.; Nagarathnam, D.; Gopal, D.; He, H.-M.; Lin, C. M.; Hamel, E. Synthesis and Evaluation of Analogues of (Z)-1-(4-Methoxyphenyl)-2-(3,4,5- Trimethoxyphenyl)Ethene as Potential Cytotoxic and Antimitotic Agents J. Med. Chem. 1992, 35, 2293-2306
30. Couvreur, P.; Reddy, L. H.; Mangenot, S.; Poupaert, J. H.; Desmaële, D.; Lepêtre-Mouelhi, S.; Pili, B.; Bourgaux, C.; Amenitsch, H.; Ollivon, M. Discovery of New Hexagonal Supramolecular Nanostructures Formed by Squalenoylation of an Anticancer Nucleoside Analogue Small 2008, 4, 247-253
31. Grant, D. S.; Williams, T. L.; Zahaczewsky, M.; Dicker, A. P. Comparison of Antiangiogenic Activities using Paclitaxel (Taxol) and Docetaxel (Taxotere) Int. J. Cancer 2003, 104, 121-129
32. Scholzen, T.; Gerdes, J. The Ki-67 Protein: from the Known and the Unknown J. Cell. Physiol. 2000, 182, 311-322
33. Nielsen, J. S.; McNagny, K. M. Novel Functions of the CD34 Family J. Cell Sci. 2008, 121, 3682-3692
34. Desmaële, D.; Gref, R.; Couvreur, P. Squalenoylation: A Generic Platform for Nanoparticular Drug Delivery J. Controlled Release 2012, 161, 609-618
35. Bildstein, L.; Pili, V.; Marsaud, V.; Wack, S.; Meneau, F.; Lepêtre-Mouelhi, S.; Desmaële, D.; Bourgaux, C.; Couvreur, P.; Dubernet, C. Interaction of an Amphiphilic Squalenoyl Prodrug of Gemcitabine with Cellular Membranes Eur. J. Pharm. Biopharm. 2011, 79, 612-620
36. Giavazzi, R.; Jessup, J. M.; Campbell, D. E.; Walker, S. M.; Fidler, I. J. Experimental Nude Mouse Model of Human Colorectal Cancer Liver Metastases JNCI, J. Natl. Cancer Inst. 1986, 77, 1303-1308
37. Spiga, S.; Acquas, E.; Puddu, M. C.; Mulas, G.; Lintas, A.; Diana, M. Simultaneous Golgi-Cox and Immunofluorescence Using Confocal Microscopy Brain Struct. Funct. 2011, 216, 171-182